Assignee
SANGAMO THERAPEUTICS INC
US·88 granted patents·73 pending applications·178 citations·filing 2014–2025
Top patents by PatentIndex Score
161 records- 0196US10669557B2Targeted deletion of cellular DNA sequencesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Jun 2, 2020·13 cites·7 claims
- 0296US10196651B2Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·16 cites·17 claims
- 0396US10113207B2Methods and compositions for targeted single-stranded cleavage and targeted integrationSANGAMO THERAPEUTICS INC·Filed 2017·Granted Oct 30, 2018·19 cites·12 claims
- 0495US10196652B2Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 5, 2019·11 cites·21 claims
- 0594US10293000B2Methods and compositions for the treatment of lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2017·Granted May 21, 2019·10 cites·7 claims
- 0694US10066242B2Artificial nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2017·Granted Sep 4, 2018·5 cites·18 claims
- 0792US11136599B2Artifical nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2020·Granted Oct 5, 2021·2 cites·9 claims
- 0892US10143760B2Liver-specific constructs, factor VIII expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2016·Granted Dec 4, 2018·7 cites·34 claims
- 0992US9833479B2Gene correction of SCID-related genes in hematopoietic stem and progenitor cellsSANGAMO THERAPEUTICS INC·Filed 2017·Granted Dec 5, 2017·5 cites·9 claims
- 1091US10975375B2Methods and compositions for regulation of transgene expressionSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 13, 2021·3 cites·11 claims
- 1191US10640790B2Artificial nucleases including engineered FokI cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2018·Granted May 5, 2020·3 cites·10 claims
- 1291US10563184B2Regulation of gene expression using engineered nucleasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Feb 18, 2020·7 cites·26 claims
- 1391US10253333B2DNA-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 9, 2019·5 cites·12 claims
- 1490US10500229B2Targeted disruption of the MHC cell receptorSANGAMO THERAPEUTICS INC·Filed 2016·Granted Dec 10, 2019·6 cites·8 claims
- 1589US11452782B2Liver-specific constructs factor VIII expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2018·Granted Sep 27, 2022·3 cites·26 claims
- 1689US10435677B2Genetically modified human cell with a corrected mutant sickle cell mutationSANGAMO THERAPEUTICS INC·Filed 2015·Granted Oct 8, 2019·8 cites·9 claims
- 1789US10407476B2Methods and compositions for treating hemophiliaSANGAMO THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·4 cites·11 claims
- 1888US10968261B2Methods and compositions for genome engineeringSANGAMO THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·2 cites·12 claims
- 1988US10265377B2Methods and compositions for treating Huntington's DiseaseSANGAMO THERAPEUTICS INC·Filed 2016·Granted Apr 23, 2019·4 cites·15 claims
- 2087US10975393B2Engineered target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Apr 13, 2021·2 cites·16 claims
- 2187US10808020B2Nuclease-mediated regulation of gene expressionSANGAMO THERAPEUTICS INC·Filed 2016·Granted Oct 20, 2020·6 cites·25 claims
- 2286US11981967B2Engineering AAVSANGAMO THERAPEUTICS INC·Filed 2020·Granted May 14, 2024·5 cites·20 claims
- 2386US11661612B2DNA-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2019·Granted May 30, 2023·1 cites·12 claims
- 2486US11040115B2Method for the treatment of lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Jun 22, 2021·1 cites·7 claims
- 2586US2025129181A1T cell modifying compounds and uses thereofSANGAMO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2686US2023414710A1Methods and compositions for treating huntington's diseaseSANGAMO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2785US11123443B2Htt repressors and uses thereofSANGAMO THERAPEUTICS INC·Filed 2019·Granted Sep 21, 2021·2 cites·9 claims
- 2885US10960085B2Modulation of liver genesSANGAMO THERAPEUTICS INC·Filed 2017·Granted Mar 30, 2021·3 cites·19 claims
- 2985US10619154B2Nuclease-mediated regulation of gene expressionSANGAMO THERAPEUTICS INC·Filed 2018·Granted Apr 14, 2020·3 cites·12 claims
- 3084US10858416B2Methods and compositions for modification of a HLA locusSANGAMO THERAPEUTICS INC·Filed 2018·Granted Dec 8, 2020·1 cites·9 claims
- 3183US10450585B2Delivery methods and compositions for nuclease-mediated genome engineeringSANGAMO THERAPEUTICS INC·Filed 2016·Granted Oct 22, 2019·6 cites·13 claims
- 3283US2024229079A9Engineered target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3382US11235026B2Methods and compositions for modulating PD1SANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 1, 2022·1 cites·7 claims
- 3482US10828376B2Liver-specific constructs and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2018·Granted Nov 10, 2020·1 cites·13 claims
- 3581US11725192B2Separation and quantification of empty and full viral capsid particlesSANGAMO THERAPEUTICS INC·Filed 2020·Granted Aug 15, 2023·2 cites·24 claims
- 3681US2023416775A1Methods and compositions for treatment of a genetic conditionSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3780US11725218B2Artificial nucleases comprising engineered cleavage half-domainsSANGAMO THERAPEUTICS INC·Filed 2021·Granted Aug 15, 2023·0 cites·18 claims
- 3879US10918668B2Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2018·Granted Feb 16, 2021·1 cites·9 claims
- 3979US2022331447A1Methods of treating lysosomal storage diseasesSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4079US2022356493A1Dna-binding proteins and uses thereofSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4179US2022316016A1Methods and compositions for targeted single-stranded cleavage and targeted integrationSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4278US11690921B2Delivery of target specific nucleasesSANGAMO THERAPEUTICS INC·Filed 2019·Granted Jul 4, 2023·2 cites·24 claims
- 4378US11421007B2Zinc finger protein compositions for modulation of huntingtin (Htt)SANGAMO THERAPEUTICS INC·Filed 2019·Granted Aug 23, 2022·1 cites·16 claims
- 4478US2023119850A1Liver-specific constructs, factor viii expression cassettes and methods of use thereofSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4577US11859190B2Methods and compositions for regulation of transgene expressionSANGAMO THERAPEUTICS INC·Filed 2021·Granted Jan 2, 2024·0 cites·5 claims
- 4677US2023203540A1Methods and compositions for nuclease-mediated targeted integration of transgenes into mammalian liver cellsSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4777US2023346844A1Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleasesSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4877US2022396634A1T cell modifying compounds and uses thereofSANGAMO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4976US2025313848A1Engineered genetic modulatorsSANGAMO THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5076US2021188926A1Methods and compositions for genome engineeringSANGAMO THERAPEUTICS INC·Filed 2021·Application pending·0 cites
Showing the top 50 of 161 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when SANGAMO THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →